Pharmacotherapy of uveitis

Bibliography

• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80(9):844-8
   PubMed Web of Science ®Google Scholar
• Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 1992;23:33-4
   PubMedGoogle Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140(3):509-16
   PubMed Web of Science ®Google Scholar
• Melton NR, Thomas RK. Medical management of anterior uveitis. Optom Clin 1991;1(4):71-8
   PubMedGoogle Scholar
• American Academy of Ophthalmology. Basic and Clinical Science Course; Fundamentals and Principles of Ophthalmology, Section 2 2007 – 2008
   Google Scholar
• Munoz-Fernandez S, Hidalgo V, Fernández-Melón J, Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003;30(6):1277-9
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14(Pt 3A):340-3
   PubMed Web of Science ®Google Scholar
• Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36(1):195-206
   PubMedGoogle Scholar
• Tripathi RC, Parapuram SK, Tripathi BJ, Corticosteroids and glaucoma risk. Drugs Aging 1999;15(6):439-50
   PubMed Web of Science ®Google Scholar
• Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7(4):266-9
   PubMed Web of Science ®Google Scholar
• Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica 1990;201(3):162-7
   PubMed Web of Science ®Google Scholar
• Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986;104(6):847-51
   PubMedGoogle Scholar
• Niewoehner CB, Niewoehner DE. Steroid-induced osteoporosis. Are your asthmatic patients at risk? Postgrad Med 1999;105:79-83, 87-88, 91
   PubMed Web of Science ®Google Scholar
• Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 2004;32(6):563-8
   PubMed Web of Science ®Google Scholar
• Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994;8(Pt 1):66-9
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Spalton DJ, Stanford MR, Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108(4):765-72
   PubMed Web of Science ®Google Scholar
• Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 2003;87(3):361
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, McCallum RM, Branchaud B, Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112(7):1192-8
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125(11):1478-85
   PubMedGoogle Scholar
• Kempen JH, Daniel E, Dunn JP, Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
   PubMedGoogle Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-51
   PubMed Web of Science ®Google Scholar
• Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci 1966;251(2):239-41
   PubMed Web of Science ®Google Scholar
• Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 2001;9(1):35-40
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108(6):1134-9
   PubMed Web of Science ®Google Scholar
• Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985;12(Suppl 12):35-9
   PubMedGoogle Scholar
• Braun J, Kastner P, Flaxenberg P, Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58(1):73-81
   PubMed Web of Science ®Google Scholar
• Spina CA. Azathioprine as an immune modulating drug: clinical applications. Clin Immunol Allergy 1984;4:415-46
   Google Scholar
• Chan GL, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987;7(5):165-77
   PubMed Web of Science ®Google Scholar
• Hemady RK, Baer JC, Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992;32(1):241-52
   PubMedGoogle Scholar
• Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967;87:499-511
   PubMedGoogle Scholar
• Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978;96(2):247-51
   PubMedGoogle Scholar
• Mathews JD, Crawford BA, Bignell JL, Mackay IR. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol 1969;53(5):327-30
   PubMed Web of Science ®Google Scholar
• Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989;32(7):837-43
   PubMed Web of Science ®Google Scholar
• McLeod HL, Coulthard S, Thomas AE, Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105(3):696-700
   PubMed Web of Science ®Google Scholar
• Fox RI, Herrmann ML, Frangou CG, Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
   PubMed Web of Science ®Google Scholar
• Cohen S, Cannon GW, Schiff M, Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44(9):1984-92
   PubMed Web of Science ®Google Scholar
• Robertson SM, Lang LS. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 1994;42(3-4):167-72
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT, Foster CS, Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130(4):492-513
   PubMed Web of Science ®Google Scholar
• Baltatzis S, Tufail F, Yu EN, Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110(5):1061-5
   PubMed Web of Science ®Google Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-51
   PubMed Web of Science ®Google Scholar
• Palestine AG, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporin plus bromocriptine. Transplant Proc 1988;20(3 Suppl 4):131-5
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Randomized, double-masked study of cyclosporin compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112(2):138-46
   PubMed Web of Science ®Google Scholar
• Deray GM, Benhmida M, Le Hoang P, Renal function and blood pressure in patients receiving long-term, low-dose cyclosporin therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992;117(7):578-83
   PubMed Web of Science ®Google Scholar
• Tocci MJ, Sigal NH. Recent advances in the mechanism of action of cyclosporin and FK506. Curr Opin Nephrol Hypertens 1992;1(2):236-42
   PubMedGoogle Scholar
• McAlister VC, Haddad E, Renouf E, Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6(7):1578-85
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115(6):763-9
   PubMed Web of Science ®Google Scholar
• Longoria J, Roberts RF, Marboe CC, Sirolimus (rapamycin) potentiates cyclosporin in prevention of acute lung rejection. J Thorac Cardiovasc Surg 1999;117(4):714-8
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Coleman H, Jirawuthiworavong G, The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand 2007;85(2):230-1
   PubMedGoogle Scholar
• Shanmuganathan VA, Casely EM, Raj D, The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89(6):666-9
   PubMed Web of Science ®Google Scholar
• Martin DF, DeBarge LR, Nussenblatt RB, Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995;154(2):922-7
   PubMed Web of Science ®Google Scholar
• Buech G, Bertelmann E, Pleyer U, Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther 2007;23(3):292-303
   PubMed Web of Science ®Google Scholar
• Moro JA, Almenar L, Martinez-Dolz L, Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008;40(9):3034-6
   PubMed Web of Science ®Google Scholar
• Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol 2008;2(4):693-702
   PubMedGoogle Scholar
• Cunningham MA, Austin BA, Li Z, LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci 2009;50(1):249-55
   PubMed Web of Science ®Google Scholar
• Roda E. Uveitis treated with nitrogen mustard. Am J Ophthalmol 1952;35(1):114
   PubMedGoogle Scholar
• Brubaker R, Font RL, Shepherd EM. Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone. Arch Ophthalmol 1971;86(5):517-24
   PubMedGoogle Scholar
• Fauci AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med 1978;64(5):890-4
   PubMed Web of Science ®Google Scholar
• Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968;11(2):151-61
   PubMed Web of Science ®Google Scholar
• Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology 1990;97(7):892-8
   PubMed Web of Science ®Google Scholar
• Austin HA III, Klippel JH, Balow JE, Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314(10):614-9
   PubMed Web of Science ®Google Scholar
• Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004;111(5):960-5
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Baltatzis S, Ekong A, Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002;109(1):137-42
   PubMed Web of Science ®Google Scholar
• Mudun BA, Ergen A, Ipcioglu SU, Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001;9(4):219-29
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121(4):437-40
   PubMedGoogle Scholar
• Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):ii51-3
   PubMed Web of Science ®Google Scholar
• Reiff A, Takei S, Sadeghi S, Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44(6):1411-5
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Iqbal I, Nadeshwar P, Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002;25(3):173-97
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, García-Delpech S, Salom D, Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24(3):351-61
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007;21(6):824-5
   PubMed Web of Science ®Google Scholar
• Takase K, Ohno S, Ideguchi H, Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2009. [Epub ahead of print]
   Google Scholar
• Biester S, Deuter C, Michels H, Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91(3):319-24
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castañeda RA, Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91(10):1341-4
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Kotaniemi K, Lindahl P, Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47(3):3397-44
   Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149(4):572-5
   PubMed Web of Science ®Google Scholar
• Huynh N, Cervantes-Castaneda RA, Bhat P, Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm 2008;16(3):89-93
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65(12):1631-4
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rødevand E, Holck P, Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68(5):696-701
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mease P, Dijkmans BA, Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68(12):1863-9
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7(3):251-9
   PubMed Web of Science ®Google Scholar
• Triolo G, Vadala M, Accardo-Palumbo A, Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 2002;61(6):560-1
   PubMed Web of Science ®Google Scholar
• Breban M, Vignon E, Claudepierre P, Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002;41(11):1280-5
   PubMed Web of Science ®Google Scholar
• Mangge H, Heinzl B, Grubbauer HM, Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 2003;23(5):258-61
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Valverde VR, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48(8):2122-7
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48(8):2224-33
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castaneda RA, Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91(10):1341-4
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS, Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112(5):764-70
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, David K, Morris J, Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporin, and corticosteroids. Transplant Proc 2005;37(2):1333-9
   PubMed Web of Science ®Google Scholar
• Stratta RJ, Alloway RR, Lo A, A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc 2005;37(8):3531-4
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-6
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008;16(5):230-2
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008;18(3):306-8
   PubMed Web of Science ®Google Scholar